Epigral Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Results
Epigral share price Rs 1,083.10 on 16 September 2026, down 0.83%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 100.00 crore. Q2 FY26 base a profit of Rs 51.00 crore.
Quick Answer
The Epigral Q2 results date for FY27 is not confirmed, and Epigral Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 587.00 crore in revenue and a profit of Rs 51.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Epigral Q2 results FY27 announcement is the next scheduled earnings event for Epigral Ltd., Epigral, formerly Meghmani Finechem, manufactures chlor-alkali and specialty chemical products including caustic soda, chloromethanes and other derivatives used in pharmaceutical, agrochemical and other industrial applications.. The stock traded at Rs 1,083.10 on the NSE on 16 September 2026, down 0.83% from the previous close of Rs 1,092.20, about 40.1% below its 52-week high of Rs 1,808.80 and 34.2% above its 52-week low of Rs 807.00.
What makes the Epigral Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 587.00 crore of revenue and a profit of Rs 51.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 705.00 crore and a profit of Rs 100.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Epigral Q2 Results FY27 Date?
The Epigral Q2 results date for FY27 is not confirmed. As of 16 September 2026, Epigral Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Epigral Q2 results date becomes public through that filing rather than through any advance announcement.
The Epigral Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Epigral.
Epigral Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Epigral Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Epigral. The Epigral Q2 results watchlist below is built from what the company has actually reported and disclosed.
Epigral Q2 results for the September 2026 quarter follow a revenue trend that has been relatively steady with one notable step-up. Revenue was Rs607 crore in June 2025, dipped slightly to Rs587 crore in September 2025, held near that level at Rs597 crore in December 2025, then rose to Rs736 crore in March 2026 before easing to Rs705 crore in the June 2026 quarter. This range-bound pattern, with revenue moving mostly between Rs587 crore and Rs736 crore across the five quarters, is the backdrop against which Epigral Q2 results will be judged. The March 2026 quarter stands out as the highest revenue quarter in this run, and how the specialty chemicals demand environment evolves from there is one of the questions Epigral Q2 results for the September 2026 quarter will help answer, based only on the historical pattern shown here rather than any specific projection.
Operating margin behind Epigral Q2 results has stayed healthy throughout, moving from 27% in June 2025 to 22% in September 2025, dipping to 17% in December 2025, then recovering to 23% in March 2026 and 25% in June 2026, with no quarter showing an operating loss. Net profit, however, tells a more complicated story that matters for how Epigral Q2 results should be read: the Rs161 crore net profit reported in June 2025 was a clear outlier compared with the Rs39 crore to Rs100 crore reported in the four quarters since, and the screener data attributes this to an unusual tax rate that quarter, effectively a net tax credit, rather than to a genuine step-up in operating performance. Net profit came in at Rs51 crore, Rs39 crore, Rs81 crore and Rs100 crore in the four quarters since, a more representative run-rate. Investors following Epigral Q2 results should treat the June 2025 profit figure as a one-off rather than a base for comparison.
On valuation, Epigral Q2 results arrive with the stock trading at a trailing P/E of about 17.3x against a book value of Rs515 per share, supported by a return on equity of 16.0% and return on capital employed of 15.5%, alongside a modest dividend yield of 0.46%. The single biggest data-quality caveat to carry into Epigral Q2 results for the September 2026 quarter is the June 2025 net profit figure of Rs161 crore, which the underlying data flags as driven by an unusual, one-off tax credit rather than genuine operating strength, since operating profit that quarter was in line with, not dramatically above, other quarters. Anyone using trailing twelve-month earnings to value the stock ahead of Epigral Q2 results should be aware that this one quarter skews the average upward, and none of the historical figures discussed here say anything about what the September 2026 quarter will actually report.
Check Epigral Ltd. Live Fundamentals on the Univest Screener
Epigral Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Epigral Ltd. reported revenue of Rs 705.00 crore in Q1 FY27, up 16.14% from Rs 607.00 crore in Q1 FY26, and a profit of Rs 100.00 crore at the net level, down 37.89% from Rs 161.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 4.21% over the March 2026 quarter figure of Rs 736.00 crore, and net profit was up 23.46% from Rs 81.00 crore in Q4 FY26. Operating margin stood at 27.0% in Q1 FY27 against 22.0% in the September 2025 quarter, which is the comparison the Epigral Q2 results print will be read against.
Q2 FY26 Base: The Comparison Epigral Q2 Results FY27 Must Beat
Epigral Ltd. reported revenue of Rs 587.00 crore and a profit of Rs 51.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Epigral Q2 results preview.
Net profit in that base quarter was below the Rs 100.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 587.00 crore sits below the Rs 705.00 crore of the June 2026 quarter, which frames how much sequential movement the Epigral Q2 results print needs to show growth.
Epigral Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 587.00 | 51.00 |
| Q3 FY26 (Dec 2025) | 597.00 | 39.00 |
| Q4 FY26 (Mar 2026) | 736.00 | 81.00 |
| Q1 FY27 (Jun 2026) | 705.00 | 100.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Epigral Q2 results preview uses.
Revenue across those four quarters ranged from Rs 587.00 crore to Rs 736.00 crore, and net profit from Rs 39.00 crore to Rs 100.00 crore. That spread is the honest context for the Epigral Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Epigral Q2 Results FY27
The Epigral Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Epigral has already reported.
Valuation Snapshot
Epigral trades at a trailing P/E of 17.26x on an EPS of Rs62.76, with a book value of Rs515 per share putting the price-to-book ratio at 2.1x on a current market price of around Rs1,083.1. Return on equity of 16.0% is healthy for a specialty chemicals manufacturer, and the stock also carries a modest dividend yield of 0.46%, giving shareholders a small income component alongside potential price gains. At a market capitalisation of about Rs4,684 crore, the valuation multiples look reasonable against the return ratios, though the trailing earnings base includes the one-off tax-driven profit spike from the June 2025 quarter, which is worth keeping in mind when comparing the P/E to historical norms.
Technical and Price Context
Epigral’s 52-week range spans a low of Rs807.0 to a high of Rs1,808.8, and the current market price of about Rs1,083.1 sits well below both the 50-day moving average of Rs1,128.88 and the 200-day moving average of Rs1,130.75. This positioning below both moving averages points to a stock in a period of price weakness relative to its own recent history. The RSI reading of 24.33 is in oversold territory, below the typical 30 threshold, suggesting selling pressure has dominated in the recent period even as the stock trades well off its 52-week high.
Balance Sheet and Payout
Epigral carries a low debt-to-equity ratio of 0.26, indicating limited borrowings relative to its equity base, a comfortable position for a chemicals manufacturer with ongoing capacity needs. The stock pays a modest dividend yield of 0.46%, giving shareholders a small but real cash return alongside the potential for price appreciation. Combined with a healthy return on equity of 16.0% and no loss-making quarter in the trailing five-quarter record, aside from the tax-driven profit anomaly in June 2025, the balance sheet profile is that of a conservatively funded, profitable specialty chemicals business.
Epigral Q2 Results FY27: Share Price and Valuation Going Into the Print
Epigral share price today is Rs 1,083.10 on the NSE, down Rs 9.10 or 0.83% from the previous close of Rs 1,092.20 on 16 September 2026, ahead of the Epigral Q2 results announcement.
| Metric | Value (16 September 2026) |
|---|---|
| NSE Symbol | EPIGRAL |
| Current Market Price | Rs 1,083.10 |
| 52-Week High | Rs 1,808.80 |
| 52-Week Low | Rs 807.00 |
| Market Capitalisation | Rs 4684 crore |
| PE Ratio | 17.26 |
| PB Ratio | 2.10 |
| EPS (TTM) | Rs 62.76 |
| Book Value per Share | Rs 515.00 |
| Debt to Equity | 0.26 |
| Return on Equity | 16.0% |
| 50-Day Moving Average | Rs 1128.88 |
| 200-Day Moving Average | Rs 1130.75 |
| RSI (14) | 24.33 |
The stock trades below both its 50-day average of Rs 1128.88 and its 200-day average of Rs 1130.75, with a 14-day RSI of 24.33. None of this is a view on where the shares go once the Epigral Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Epigral Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Epigral Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Epigral Q2 results print in proportion.
- Revenue against the Rs 587.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 51.00 crore in that same quarter
- Operating margin against 27.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Epigral Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Epigral Q2 Results FY27
The Epigral Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Epigral Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Epigral Q2 results FY27 print faces a base of Rs 587.00 crore in revenue and a profit of Rs 51.00 crore, with the most recent quarter having delivered Rs 705.00 crore and a profit of Rs 100.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Epigral, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Epigral Q2 Results FY27
What is the Epigral Q2 results date for FY27?
Ans. The Epigral Q2 results date for FY27 is not confirmed. Epigral Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Epigral Q2 results 2026 cover?
Ans. The Epigral Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Epigral Ltd. reports revenue, operating profit and net profit for that period, and the Epigral Q2 results filing also carries the notes to the accounts.
What were the Epigral Q1 FY27 results?
Ans. Epigral Ltd. reported revenue of Rs 705.00 crore in Q1 FY27 and a profit of Rs 100.00 crore at the net level. Revenue was up 16.14% versus Q1 FY26 and net profit was down 37.89% from Rs 161.00 crore in Q1 FY26.
What were Epigral Q2 FY26 results in the September 2025 quarter?
Ans. Epigral Ltd. reported revenue of Rs 587.00 crore and a profit of Rs 51.00 crore in Q2 FY26. Operating margin was 22.0%. Those figures form the base for the Epigral Q2 results FY27 comparison.
What are the main Epigral Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Epigral Q2 results expectations centre on revenue against the Rs 587.00 crore base, net profit against a profit of Rs 51.00 crore, operating margin against 27.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Epigral share price today ahead of the Q2 earnings?
Ans. Epigral share price is Rs 1,083.10 on the NSE as of 16 September 2026, down 0.83% from Rs 1,092.20. The stock is about 40.1% below its 52-week high of Rs 1,808.80 and 34.2% above its 52-week low of Rs 807.00, at a market capitalisation of Rs 4684 crore.
Is Epigral a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Epigral Ltd. The stock trades at a price-to-book ratio of 2.10 with a return on equity of 16.0%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
